Spots Global Cancer Trial Database for squamous cell carcinoma of head and neck
Every month we try and update this database with for squamous cell carcinoma of head and neck cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety and Efficacy Study of P276-00 in Combination With Radiation in Subjects With Advanced Head and Neck Cancer | NCT00899054 | Squamous Cell C... | P276-00 External beam r... | 18 Years - | Piramal Enterprises Limited | |
| A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours | NCT05605522 | Pancreatic Duct... Squamous Cell C... Colorectal Canc... Gastric Cancer Ewing Sarcoma NTSR1 Expressin... Neuroendocrine ... | [225]-FPI-2059 [111In]-FPI-205... | 18 Years - | Fusion Pharmaceuticals Inc. | |
| Changes in Body Composition After EPA Supplementation in Head and Neck Patients | NCT02715596 | Squamous Cell C... | EPA supplementa... Placebo | 18 Years - | Institut Català d'Oncologia | |
| Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies | NCT04465487 | Squamous Cell C... | REGN6569 Cemiplimab | 18 Years - | Regeneron Pharmaceuticals | |
| TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | NCT03829436 | Hepatocellular ... Metastatic Cast... Renal Cell Carc... Non-small Cell ... Colorectal Canc... Squamous Cell C... Triple-Negative... Urothelial Carc... Cholangiocarcin... GastroEsophagea... Pancreatic Canc... Sarcoma | Part 1 TPST-112... Part 2 TPST-112... Part 3 TPST-112... Part 4 TPST-112... | 18 Years - | Tempest Therapeutics | |
| Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Cancer: Impact of Virtual Implants Visualisation on Dosimetry (OPPIDOM) | NCT04801472 | Squamous Cell C... Oropharyngeal S... Oral Cavity Squ... | Optimisation of... | 18 Years - | Institut de cancérologie Strasbourg Europe | |
| Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN | NCT04939480 | Squamous Cell C... | Atezolizumab | 18 Years - | University Hospital, Essen | |
| A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers | NCT04879849 | Carcinoma, Non-... Triple Negative... Squamous Cell C... | Pembrolizumab TAK-676 Image-guided ra... | 18 Years - | Takeda | |
| Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole | NCT00038038 | Squamous Cell C... Head and Neck N... Metastases, Neo... | 18F-fluoromison... PET scan | 18 Years - | M.D. Anderson Cancer Center | |
| Dendritic Cell Vaccine for Head and Neck Cancer | NCT00492947 | Squamous Cell C... | dendritic cell ... | 18 Years - | University of Maryland, Baltimore | |
| sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC | NCT04091867 | Squamous Cell C... | sEphB4-HSA with... Cetuximab Radiation Thera... | 18 Years - 100 Years | University of Colorado, Denver | |
| Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin | NCT04502888 | Cutaneous Squam... Squamous Cell C... | Drug: SL-172154 | 18 Years - | Shattuck Labs, Inc. | |
| A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN) | NCT05027204 | Squamous Cell C... | Docetaxel Nivolumab | 18 Years - | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | |
| A Phase 1b Study of WU-NK-101 in Combination With Cetuximab | NCT05674526 | Colorectal Canc... Squamous Cell C... | WU-NK-101 - Dos... Cetuximab - Dos... WU-NK-101 - Coh... Cetuximab - Coh... | 18 Years - | Wugen, Inc. | |
| PABLIXIMAB as Neoadjuvant Therapy for Head and Neck Squamous-cell Carcinoma | NCT06125223 | Squamous Cell C... Neoadjuvant The... Immunotherapy | 18 Years - 80 Years | Xijing Hospital | ||
| Pembrolizumab Plus Olaparib in LA-HNSCC | NCT05366166 | Squamous Cell C... | Pembrolizumab Olaparib Cisplatin IMRT (intensity... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| A Study of MGC026 in Participants With Advanced Solid Tumors | NCT06242470 | Advanced Solid ... Advanced Cancer Metastatic Canc... Squamous Cell C... Non Small Cell ... Small-cell Lung... Bladder Cancer Sarcoma Endometrial Can... Melanoma Castration Resi... Cervical Cancer Colorectal Canc... Gastric Cancer Gastro-esophage... Pancreas Cancer Clear Cell Rena... Hepatocellular ... Platinum-resist... | MGC026 Dose Esc... MGC026 Dose for... | 18 Years - | MacroGenics | |
| Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck | NCT00233636 | Head and Neck C... Carcinoma, Squa... | Iressa (Gefitin... Radiotherapy | 18 Years - | AstraZeneca | |
| A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | NCT04260802 | Cancer Neoplasms Metastatic Canc... Triple Negative... Gastric Cancer Cervical Cancer Ovarian Cancer Hepatocellular ... Squamous Cell C... Urothelial Carc... Urothelial Neop... Non Small Cell ... Renal Cell Carc... Locally Advance... Locally Advance... Squamous Cell C... Sarcoma Merkel Cell Car... Bladder Cancer | OC-001 OC-001 in Combi... | 18 Years - | Ocellaris Pharma, Inc. | |
| A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers | NCT05544929 | Carcinoma, Non-... Cutaneous Melan... Carcinoma, Rena... Carcinoma, Ovar... Nasopharyngeal ... Carcinoma, Thym... Anal Cancer Mesothelioma Esophagogastric... High Microsatel... Squamous Cell C... Triple Negative... | KFA115 pembrolizumab | 18 Years - | Novartis | |
| A Study of MGC026 in Participants With Advanced Solid Tumors | NCT06242470 | Advanced Solid ... Advanced Cancer Metastatic Canc... Squamous Cell C... Non Small Cell ... Small-cell Lung... Bladder Cancer Sarcoma Endometrial Can... Melanoma Castration Resi... Cervical Cancer Colorectal Canc... Gastric Cancer Gastro-esophage... Pancreas Cancer Clear Cell Rena... Hepatocellular ... Platinum-resist... | MGC026 Dose Esc... MGC026 Dose for... | 18 Years - | MacroGenics | |
| Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck | NCT00459043 | Squamous Cell C... | ZD6474 Docetaxel | 18 Years - | Dana-Farber Cancer Institute | |
| Toripalimab in Combined With Cetuximab，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC | NCT06081582 | Squamous Cell C... | Toripalimab | 18 Years - | First Affiliated Hospital of Zhejiang University | |
| Optimised Early Management of Squamous Cell Carcinoma of the Head and Neck Cancer | NCT04528420 | Squamous Cell C... | optimised manag... | 18 Years - 75 Years | Centre Henri Becquerel | |
| Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) | NCT04428151 | Squamous Cell C... | Lenvatinib Pembrolizumab Docetaxel Capecitabine Paclitaxel Cetuximab Lenvatinib | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer | NCT06110195 | Head and Neck C... Head and Neck N... Squamous Cell C... | Xevinapant Carboplatin Paclitaxel Radiation Thera... | 18 Years - | University of Chicago | |
| Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors | NCT04344795 | Solid Tumor Colorectal Canc... Non Small Cell ... Squamous Cell C... Urothelial Carc... Endometrial Can... Gastroesophagea... Gastric Adenoca... Solid Tumors Wi... | TPST-1495 twice... TPST-1495 once ... Pembrolizumab | 18 Years - | Tempest Therapeutics | |
| A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN) | NCT05027204 | Squamous Cell C... | Docetaxel Nivolumab | 18 Years - | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | |
| Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | NCT04429542 | Head and Neck S... Squamous Cell C... Colorectal Canc... Squamous Cell C... EGFR Amplificat... Epithelial Ovar... Pancreas Cancer Cutaneous Squam... Head and Neck N... Carcinoma, Squa... Squamous Cell C... | BCA101 Pembrolizumab | 18 Years - | Bicara Therapeutics | |
| Changes in Body Composition After EPA Supplementation in Head and Neck Patients | NCT02715596 | Squamous Cell C... | EPA supplementa... Placebo | 18 Years - | Institut Català d'Oncologia | |
| MGC018 With or Without MGA012 in Advanced Solid Tumors | NCT03729596 | Squamous Cell C... Triple Negative... Melanoma Advanced Solid ... Metastatic Cast... Non Small Cell ... | vobramitamab du... | 18 Years - | MacroGenics | |
| Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell Carcinoma | NCT04428047 | Squamous Cell C... | bintrafusp alfa | 18 Years - | UNICANCER | |
| A Beta-only IL-2 ImmunoTherapY Study | NCT05086692 | Advanced Solid ... Unresectable So... Clear Cell Rena... Triple Negative... Non-Small Cell ... Non-Small Cell ... Colorectal Canc... Gastric Cancer Cervical Cancer Basal Cell Carc... Bladder Cancer Merkel Cell Car... Squamous Cell C... Cutaneous Squam... Pleural Mesothe... Esophageal Canc... Endometrial Car... Solid Tumor Solid Tumor, Ad... MSI-H Solid Mal... Cancer With A H... Epithelial Ovar... Primary Periton... Gastroesophagea... Acral Melanoma Mucosal Melanom... Cutaneous Melan... DMMR Solid Mali... Fallopian Tube ... Ovarian Cancer MSI-H Cancer DMMR Cancer Pancreas Adenoc... Skin Cancer | MDNA11 Pembrolizumab | 18 Years - | Medicenna Therapeutics, Inc. | |
| Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Cancer: Impact of Virtual Implants Visualisation on Dosimetry (OPPIDOM) | NCT04801472 | Squamous Cell C... Oropharyngeal S... Oral Cavity Squ... | Optimisation of... | 18 Years - | Institut de cancérologie Strasbourg Europe | |
| Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN | NCT04939480 | Squamous Cell C... | Atezolizumab | 18 Years - | University Hospital, Essen | |
| Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer | NCT06110195 | Head and Neck C... Head and Neck N... Squamous Cell C... | Xevinapant Carboplatin Paclitaxel Radiation Thera... | 18 Years - | University of Chicago | |
| Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer | NCT05620134 | Cancer Tumor, Solid Advanced Solid ... Metastatic Canc... Melanoma Colorectal Canc... Non-small Cell ... Small-cell Lung... Urothelial Carc... Squamous Cell C... Luminal Breast ... Triple Negative... Clear Cell Rena... Papillary Renal... Gastric Adenoca... GastroEsophagea... Squamous Cell C... Pancreatic Aden... Hepatocellular ... Colorectal Aden... Epithelial Ovar... Thyroid Cancer | JK08 Pembrolizumab | 18 Years - | Salubris Biotherapeutics Inc | |
| Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer | NCT03829501 | Squamous Cell C... Non-small Cell ... Hepatocellular ... Esophageal Canc... Gastric Cancer Melanoma Renal Cell Carc... Pancreatic Canc... Cervical Cancer Triple Negative... Advanced Cancer Metastatic Canc... | KY1044 KY1044 and atez... | 18 Years - | Kymab Limited | |
| Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1 | NCT04795713 | Advanced Solid ... Non-small Cell ... Squamous Cell C... | MT-6402 | 18 Years - | Molecular Templates, Inc. | |
| A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204) | NCT05061420 | Squamous Cell C... | Pembrolizumab SAR444245 (Thor... Cetuximab | 18 Years - | Sanofi | |
| ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer | NCT05182866 | Head and Neck C... Squamous Cell C... | ASP-1929 Photoi... | 18 Years - | Rakuten Medical, Inc. | |
| A Standardized Intervention to Improve the Management of Chemotherapy-induced Nausea and Vomiting | NCT05792228 | Squamous Cell C... Chemotherapy In... | nurse-led stand... | 18 Years - | Tianjin Medical University Cancer Institute and Hospital | |
| Study of Docetaxel in Combination With Cisplatin and 5-Fluorouracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck | NCT00139269 | Advanced Squamo... Squamous Cell C... SSCHN | Docetaxel Cisplatin 5-Fluorouracil | 18 Years - | Dana-Farber Cancer Institute | |
| PABLIXIMAB as Neoadjuvant Therapy for Head and Neck Squamous-cell Carcinoma | NCT06125223 | Squamous Cell C... Neoadjuvant The... Immunotherapy | 18 Years - 80 Years | Xijing Hospital | ||
| Study to Evaluate the Response Rate to Therapy With Docetaxel and Cisplatin in Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck | NCT02061631 | Squamous Cell C... | Cisplatin DOCETAXEL XRP69... Dexamethasone Dexamethasone | 18 Years - 64 Years | Sanofi | |
| Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region | NCT05482880 | Cutaneous Squam... Cutaneous Squam... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Skin Cancer High-Risk Cance... Quality of Life Satisfaction, P... | Regular care wi... | 18 Years - | Maastricht University Medical Center | |
| A Study of MGC026 in Participants With Advanced Solid Tumors | NCT06242470 | Advanced Solid ... Advanced Cancer Metastatic Canc... Squamous Cell C... Non Small Cell ... Small-cell Lung... Bladder Cancer Sarcoma Endometrial Can... Melanoma Castration Resi... Cervical Cancer Colorectal Canc... Gastric Cancer Gastro-esophage... Pancreas Cancer Clear Cell Rena... Hepatocellular ... Platinum-resist... | MGC026 Dose Esc... MGC026 Dose for... | 18 Years - | MacroGenics | |
| Quantifying Systemic Immunosuppression to Personalize Cancer Therapy | NCT04941365 | Metastatic Mela... Metastatic Brea... Advanced Renal ... Squamous Cell C... Non-small Cell ... Healthy | single arm | 18 Years - 90 Years | Institut du Cancer de Montpellier - Val d'Aurelle | |
| A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors | NCT05462873 | Carcinoma, Non-... Carcinoma, Rena... Esophageal Squa... Squamous Cell C... | QEQ278 | 18 Years - | Novartis | |
| Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole | NCT00038038 | Squamous Cell C... Head and Neck N... Metastases, Neo... | 18F-fluoromison... PET scan | 18 Years - | M.D. Anderson Cancer Center | |
| Needs and Preferences of Patients With Head-neck Cutaneous SCC | NCT06046625 | Cutaneous Squam... Cutaneous Squam... Squamous Cell C... Squamous Cell C... Squamous Cell C... Skin Cancer Patient Satisfa... High-Risk Cance... Preference, Pat... Decision Making Interview | Regular care wi... | 18 Years - | Maastricht University Medical Center | |
| Stereotactic Body Radiotherapy for Head and Neck Tumors | NCT01344356 | Squamous Cell C... Nasopharyngeal ... Salivary Gland ... Head and Neck S... Paraganglioma o... Chordoma of Hea... Chondrosarcoma ... Angiofibroma of... | stereotactic bo... Stereotactic bo... | 18 Years - | Mercy Research | |
| App-based Recording and Optimization of the Nutritional Status in Patients With Head and Neck Tumors During and After Radio(Chemo)Therapy | NCT06367257 | Squamous Cell C... | App Usage Standard of Car... | 18 Years - | University of Erlangen-Nürnberg Medical School | |
| Albumin-bound Paclitaxel Combined With Cisplatin Versus Docetaxel Combined With Cisplatin Induced Chemotherapy in Advanced Head and Neck Squamous Tummor | NCT04766827 | Squamous Cell C... | albumin-bound p... | 18 Years - | Tianjin Medical University Cancer Institute and Hospital | |
| A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | NCT05271604 | Head and Neck C... Squamous Cell C... Recurrent Squam... Metastatic Canc... Metastatic Squa... | Ozuriftamab Ved... PD-1 inhibitor | 18 Years - | BioAtla, Inc. | |
| INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | NCT05359692 | Metastatic Head... Advanced Malign... Recurrent Head ... | INCAGN01876 retifanlimab | 18 Years - 99 Years | Incyte Corporation | |
| A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers | NCT04892875 | Head and Neck C... Squamous Cell C... Oral Cavity Squ... Oral Cavity Can... Oropharynx Canc... Oropharynx Squa... Larynx Cancer Pharynx Cancer Hypopharynx Can... Hypopharynx Squ... | Zimberelimab Etrumadenant Cisplatin Radiation | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck | NCT00756444 | Squamous Cell C... | Panitumumab Cisplatin 5FU | 18 Years - | Amgen | |
| Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck | NCT00233636 | Head and Neck C... Carcinoma, Squa... | Iressa (Gefitin... Radiotherapy | 18 Years - | AstraZeneca | |
| Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC Patients | NCT05673577 | Squamous Cell C... | Camrelizumab+ce... | 18 Years - 70 Years | Fudan University | |
| A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors | NCT05653882 | Solid Tumor Non Small Cell ... Melanoma Squamous Cell C... Renal Cell Carc... | AB248 pembrolizumab | 18 Years - | Asher Biotherapeutics, Inc. | |
| 5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC | NCT05317000 | Squamous Cell C... | Combination 5-a... 5-azacytidine Nivolumab | 18 Years - | Yale University | |
| A Study to Assess Safety of Nivolumab in Routine Oncology Practice in China | NCT04825873 | Non-Small Cell ... Squamous Cell C... | 18 Years - | Bristol-Myers Squibb | ||
| Navigation for Timely Adjuvant Therapy for Patients With Locally Advanced HNSCC | NCT04098458 | Squamous Cell C... | NDURE | 18 Years - | Medical University of South Carolina | |
| NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy | NCT03589339 | Radiotherapy Immunotherapy Microsatellite ... Metastasis From... Squamous Cell C... Metastasis From... Metastatic Rena... Metastasis From... Metastatic Trip... Metastatic NSCL... Metastasis From... | NBTXR3 SABR Nivolumab Pembrolizumab | 18 Years - | Nanobiotix | |
| TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC | NCT06236425 | Squamous Cell C... Metastatic Squa... | TBio-4101 Pembrolizumab Platinum based ... Cyclophosphamid... Fludarabine Aldesleukin | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid | NCT05578820 | Sarcoma Melanoma Squamous Cell C... Breast Neoplasm... Uterine Cervica... Vulvar Neoplasm... Penile Neoplasm... Anus Neoplasms | Intratumoral ad... Intravenous adm... | 18 Years - 75 Years | Gene Surgery LLC | |
| Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | NCT06034860 | Non Small Cell ... Hepatocellular ... Melanoma Renal Cell Carc... Microsatellite ... Mismatch Repair... Mesothelioma Esophageal Squa... Squamous Cell C... Urothelial Carc... Cervical Cancer | MT-8421 Nivolumab | 18 Years - | Molecular Templates, Inc. | |
| NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHN | NCT05802290 | Squamous Cell C... | Nivolumab 240 M... | 18 Years - | Gruppo Oncologico del Nord-Ovest | |
| Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck | NCT00459043 | Squamous Cell C... | ZD6474 Docetaxel | 18 Years - | Dana-Farber Cancer Institute | |
| MicroRNA Markers in Head and Neck Cancers | NCT04305366 | Squamous Cell C... | Tissue collecti... | 18 Years - 100 Years | University of Colorado, Denver | |
| Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. | NCT01353625 | Glioblastoma Mu... Squamous Cell C... Prostate Cancer Ewing's Osteosa... Chronic Lymphoc... Neoplasm Metast... | CC-115 | 18 Years - | Celgene | |
| Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma | NCT06046482 | Head Neck Squamous Cell C... | Pembrolizumab Magrolimab cetuximab Docetaxel | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck | NCT04665843 | Squamous Cell C... | Atezolizumab Tiragolumab Placebo | 18 Years - | Hoffmann-La Roche | |
| Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck | NCT05845307 | Squamous Cell C... | Control Group TTI-101 | 18 Years - | M.D. Anderson Cancer Center | |
| Quantifying Systemic Immunosuppression to Personalize Cancer Therapy | NCT05621837 | Melanoma Breast Cancer Renal Cell Carc... Urinary Bladder... Squamous Cell C... Small Cell Carc... NSCLC | MDSC quantifica... | 18 Years - 90 Years | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| A Phase II Clinical Trial to Study the Efficacy and Safety of a New Drug P276-00 in Treatment of Recurrent and/or Locally Advanced Head and Neck Cancer | NCT00824343 | Squamous Cell C... | P276-00 | 18 Years - | Piramal Enterprises Limited | |
| A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN) | NCT05027204 | Squamous Cell C... | Docetaxel Nivolumab | 18 Years - | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | |
| Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer | NCT02537223 | Squamous Cell C... Locoregionally ... | BYL719 Cisplatin Intensity modul... | 18 Years - | University Health Network, Toronto | |
| TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC | NCT06236425 | Squamous Cell C... Metastatic Squa... | TBio-4101 Pembrolizumab Platinum based ... Cyclophosphamid... Fludarabine Aldesleukin | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
